TPG Capital, L.P.
-9.38%
3M Return
$1.310
-0.029 (-2.24%)At close
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.
Allogene Therapeutics is not a good buy right now. The current price is $1.31, and the company has reported consistent losses, including a net income loss of $42,677,000 in Q2 2026. Additionally, the RSI is at 27.381, indicating that the stock is oversold, but this does not guarantee a price rebound. The main risk is the ongoing financial strain reflected in a negative forward P/E ratio of 0, suggesting that the company is not expected to generate profits in the near future.
JPMorgan
—
2026-04-16
JPMorgan
2026-04-16
Price Target
—
H.C. Wainwright
$11
2026-04-16
H.C. Wainwright
2026-04-16
Price Target
$11
Jefferies
$10
2026-04-15
Jefferies
2026-04-15
Price Target
$10
Baird
$9
2026-04-14
Baird
2026-04-14
Price Target
$9
Bernstein
—
2026-04-14
Bernstein
2026-04-14
Price Target
—

Cellectis Downgraded to Market Perform Amid Strategic Shift

Allogene Therapeutics CFO Geoffrey Parker to Retire

Allogene Therapeutics to Participate in Investor Conference

Allogene Therapeutics Reports Q2 Loss

Allogene Therapeutics Schedules Conference Call for December 13, 2021
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Allogene Therapeutics is not a good buy right now. The current price is $1.31, and the company has reported consistent losses, including a net income loss of $42,677,000 in Q2 2026. Additionally, the RSI is at 27.381, indicating that the stock is oversold, but this does not guarantee a price rebound. The main risk is the ongoing financial strain reflected in a negative forward P/E ratio of 0, suggesting that the company is not expected to generate profits in the near future.
4 analysts cover ALLO: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.50.
ALLO/USDT quickly shifted from excitement to exhaustion. $ALLO once surged to 0.35839, then fell for several days in a row. It is now at 0.25601, down 36.60% over 90 days. But it is still up 137.37% over 180 days. The bigger trend is green, the short-term trend is red. That gap is exactly what makes traders lose discipline. Are you trading ALLO’s trend, or its pullback?
Show more$LIT $ALLO $RAY Success in crypto, I've learned, isn't about chasing every opportunity — it's about patience, discipline, and having a clear strategy. After losing more than $9,500 trading on my own, I genuinely questioned whether I should continue. Following CY WATSON's market insights changed my approach completely. I became more disciplined, paid closer attention to market structure and timing, and learned to avoid emotional decisions. Through his copy-trading approach, I've made significant profits today — I'm grossing a profit of $23,651 from CY WATSON by just copying his trades. Seeing this progress after the losses I experienced has been incredibly rewarding. Based on my own experience, I have a lot of respect for CY WATSON's approach and would confidently recommend people interested in learning about his methods to take time and reach out to him. His username is in the comments below for anyone who wants to take a look.
Show more
$SENT $ALLO $CPOOL 🌎 MACRO IS ABOUT TO GET INTERESTING… Tonight’s market isn’t only about Bitcoin or gold. U.S. flash manufacturing and services PMI data are due, while Fed Vice Chair Michael Barr is also scheduled to speak. At the same time, oil remains around the $90 area and traders are watching developments around the Middle East and U.S.–China relations. 📊⚡ That combination can create some serious intraday volatility across BTC, ETH, gold and U.S. equities. So instead of asking, “Which coin is going 10x?” I’m asking: 👉 Where is liquidity sitting? 👉 Where are the major resistance zones? 👉 What happens if the data surprises? The next move may come from macro before crypto even gets the chance to react. 👀 #BTC #ETH #Gold #Macro #CryptoTrading
Show more
Please, stop pumping, just give me a chance! I woke up and saw $AKE surging again, already near 0.06. Why is it so easy for it to bounce back after a drop? Everyone says the unlock will bring selling, but when everyone expects the same thing, the market makers won't let it play out that way. Because if it were really that easy, then $ALLO and $LAB would have done the same before — they kept pumping right before the unlock, and when the unlock day came, there was no sell-off either, just like $LAB ranging around 15 during that period.
Show more
Just switched the software to the background, and it dropped right away — playing hide-and-seek with me? Opened the chart this morning, $ALLO was clearly under pressure at the highs, with weak support, and the overhead resistance was suffocating. I called the long-high short idea at the time, and the rhythm was on point. If the trend isn't broken, hold; if it breaks, run. Don't fall in love with a stock. From 0.24914 to 0.20142, the short wasn't held in vain, +469.19%, feels great. It was really slow before, but once it played out, it was sweet. Closed 80% first, keeping the remaining 20% protected at cost. Let profits run if it keeps dropping, and don't let a bounce turn gains into discomfort. Take profits when it's time. Don't get inflated by profits, don't despair over drawdowns. There will be more opportunities later — don't chase, wait for a more comfortable position next round. I'll flag it as soon as I see it. $ETH $XRP
Show moreThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.